title: Attenuated type II TGF-beta receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination.
abstract: We examined the effect of stable transfection of dominant negative TbetaR-II (dn TbetaR-II) cDNA in a human oral carcinoma cell line that contained normal Ras and was growth inhibited by TGF-beta1. Two clonal cell lines containing dn TbetaR-II were isolated and compared to the vector-only control and parent cell line. The treatment of cells with exogenous TGF-beta1 resulted in a decrease in ligand-induced growth inhibition and loss of c-myc downregulation in test cells compared to controls; transcriptional activation of certain genes including fra-1 and collagenase was retained. Cells containing dn TbetaR-II grew faster in monolayer culture, expressed less keratin 10 and exhibited increased motility and invasion in vitro compared to control cell lines. Endogenous TGF-beta1 production and the regulation of MMP-2 and MMP-9 by TGF-beta1 remained unchanged. After orthotopic transplantation to the floor of the mouth in athymic mice, cells containing dn TbetaR-II formed comparable numbers of primary tumours at the site of inoculation as controls but the tumours were less differentiated as demonstrated by the absence of keratin 10 immunostaining. Further, metastatic dissemination to the lungs and lymphatics was more evident in grafts of cells containing dn TbetaR-II than controls. Taken together, the results demonstrate that attenuation of TGF-beta signalling through transfection of dn TbetaR-II cDNA leads to an enhanced growth rate, a loss of tumour cell differentiation and an increase in migration and invasion, characteristics that corresponded to the development of the metastatic phenotype.
authors.affiliation: Department of Oral and Dental Science, University of Bristol, Bristol, United Kingdom.
authors.forename: Suzy P
authors.initials: SP
authors.lastname: Huntley
authors.forename: Maria
authors.initials: M
authors.lastname: Davies
authors.forename: John B
authors.initials: JB
authors.lastname: Matthews
authors.forename: Gareth
authors.initials: G
authors.lastname: Thomas
authors.forename: John
authors.initials: J
authors.lastname: Marshall
authors.forename: C Max
authors.initials: CM
authors.lastname: Robinson
authors.forename: John W
authors.initials: JW
authors.lastname: Eveson
authors.forename: Ian C
authors.initials: IC
authors.lastname: Paterson
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Prime
mesh_terms: D002454:Cell Differentiation; D002455:Cell Division; D045744:Cell Line, Tumor; D002465:Cell Movement; D006801:Humans; D053550:Keratin-10; D015603:Keratinocytes / Q000473:pathology*; D007633:Keratins / Q000032:analysis; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary; D009062:Mouth Neoplasms / Q000737:chemistry / Q000473:pathology*; D009362:Neoplasm Metastasis; D010641:Phenotype; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000502:physiology*; D015398:Signal Transduction; D016211:Transforming Growth Factor alpha / Q000494:pharmacology
chemical_list: C507493:KRT10 protein, human; D018125:Receptors, Transforming Growth Factor beta; D016211:Transforming Growth Factor alpha; D053550:Keratin-10; D007633:Keratins; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II